Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, So-Hyeon | - |
dc.contributor.author | Choi, Nam-Kyong | - |
dc.contributor.author | Kim, Ye-Jee | - |
dc.contributor.author | Seong, Jong-Mi | - |
dc.contributor.author | Shin, Ju-Young | - |
dc.contributor.author | Jung, Sun-Young | - |
dc.contributor.author | Park, Byung-Joo | - |
dc.date.accessioned | 2024-01-08T06:32:58Z | - |
dc.date.available | 2024-01-08T06:32:58Z | - |
dc.date.issued | 2015-06 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69378 | - |
dc.description.abstract | This study examined 1-year persistency with cholinesterase inhibitors (ChEIs) for the treatment of elderly Alzheimer's dementia (AD) patients in Korea. Korean Health Insurance Review & Assessment Service database from January 2005 to June 2006 was used. Patients aged 65 or older with AD diagnosis who were first prescribed a ChEI were included. The 1-year persistence, persistency rate, and switching patterns during the follow-up period were identified. Mean time to drug discontinuation was analyzed, and persistency rates between different patient factors were compared. The 1-year persistency rate of newly treated 6,461 AD patients was 24.0 %, while 50 % of study patients discontinued treatment by 91 days from initiation. Persistency rates of female patients (22.8 %), patients in rural areas (12.7 %), and primary care (10.2 %) were relatively low (p < 0.001). Persistency rate differed between age groups (p < 0.001). Overall proportion of switching was 6.6 %. The 1-year persistency rate of ChEIs for AD patients in Korea did not reach those of previous researches in other countries. Patients less likely to remain on therapy should be especially monitored to optimize treatment persistence. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12272-014-0500-8 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.38, no.6, pp 1255 - 1262 | - |
dc.identifier.kciid | ART001998144 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000355946600038 | - |
dc.identifier.scopusid | 2-s2.0-84930864988 | - |
dc.citation.endPage | 1262 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1255 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 38 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Medication persistence | - |
dc.subject.keywordAuthor | Dementia, Alzheimer type | - |
dc.subject.keywordAuthor | Cholinesterase inhibitors | - |
dc.subject.keywordAuthor | Pharmacoepidemiology | - |
dc.subject.keywordAuthor | Elderly | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | DONEPEZIL | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | COSTS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.